When offering watchful waiting or active monitoring protocols to prostate cancer (PCa) patients, differentiation between Gleason scores (GS) 6 and 7 at biopsy is important. However, upgrading after prostatectomy is common. We investigated the impact of different PSA levels on misclassification in the PSA range of 2-3.9 and 4-10 ng ml
Introduction
Regarding prostate cancer (PCa) histological estimation of needle biopsy specimens from the prostate is the first step in diagnosis and treatment decision making. Histological grade of PCa is usually assessed using the Gleason system, which is one of the key prognostic markers for this disease for predicting biochemical recurrence, systemic recurrence and overall patient survival. 1, 2 Although patients with high-grade tumors (Gleason scores, GS 7-10) experience higher rates of progression, GS 6 PCas are considered to be well differentiated tumors and patients generally have a favorable prognosis and a low risk for recurrence after therapy 3 Less invasive treatment modalities in the form of watchful waiting, active surveillance with selective delayed intervention are offered to patients with low-risk disease.
At the same time the implementation of widespread PSA-based PCa screening has led to more and more patients being diagnosed with PCa low stage and with favorable tumor grade (GS 6). As a result, opponents of screening point out the risk of over diagnosis and over treatment of PCas, which would not have been detected without screening and would probably not have done any harm to a patient with subsequent unnecessary therapy.
Therefore, accurate grading at prostate biopsy (Pbx) as a crucial step in treatment decision making is essential. However, as determined in the radical prostatectomy specimen, the final tumor GS is often higher than that determined by Pbx with the most common error being the underscoring of tumors that are subsequently shown to be radical prostatectomy GS 7. 4 As it has already been shown that upgrading after Pbx occurs often, we were interested whether there is a difference in the amount of upgrading in the two PSA groups of 2.0-3.9 ng ml À1 (low PSA group) and 4.0-10.0 ng ml À1 (intermediate PSA group) in a screening population.
The purpose of this study was to evaluate the amount of possible over and under diagnosis in patients in which a tumor was upgraded or not and if there are differences in the two PSA groups indicating that screening at low PSA levels is reasonable.
Patients and methods
From 1996 to 2006 after obtaining informed consent, 448 consecutive patients with PCa (T1c) and tPSA 2.0-10.0 ng ml À1 who underwent prostate biopsy and consecutive radical retropubic prostatectomy (RRP) were included in our study population. The study population was recruited from the Tyrol screening project. Digital rectal examination was not part of the screening protocol, although it was performed at prostate biopsy. From 1996 to 2000, 10 systematic gray-scale ultrasound guided prostate biopsy cores in a standard spatial distribution were taken, whereas from 2000 to 2005 an additional 5 color Doppler enhanced targeted biopsy cores were taken based on age-specific tPSA reference ranges. These reference ranges were defined as half the age referenced tPSA reported by Oesterling et al. 5 in combination with percent-free PSA o18%. Gray-scale ultrasonography was done using a Combison 530MT unit fitted with a biplane probe operating at a gray-scale frequency of 10 MHz and as described earlier. 6 Each biopsy core was reviewed by a single pathologist and assessed as cancerous with an assigned GS. After PCa diagnosis, RRP was performed 2 months later using an open retropubic approach. Surgical specimens were fixed in formalin, stained with hematoxylin-eosin and tumor, node, metastasis-stage and Gleason grading were performed.
Possible over diagnosis was defined as GS o7, pathological stage pT2a and negative surgical margins. Under diagnosis was defined as pathological stage pT3 or greater, or positive surgical margins. 7 Blood serum samples were obtained before any prostatic manipulation and they were evaluated at our laboratory on the same day. PSA was assessed with the IMx immunoassay.
Statistical significance among different groups was assessed trough Contingency Table analysis 
Results
Between 1996 and 2005, a total of 1178 PCa patients with tPSA 2.0-10.0 ng ml À1 who underwent RRP were assessed; 448 were diagnosed GS 6 carcinoma at Pbx and therefore considered for further investigation. Study population characteristics of the two different subgroups (tPSA 2-4 and 4-10 ng ml À1 ) assessed are shown in Table 1 . Mean age at time of diagnosis was 57.4 (range 40-74) years in the low tPSA group and 62.7 (42-78) in the intermediate tPSA group. Mean tPSA levels were 2.9 and 5.9 ng ml À1 , respectively. Free PSA levels were almost equal in both groups (15.2% vs 14.2%). Patients tended to be younger in the low tPSA range. Mean number of positive biopsy cores was 1.8 (range 1-8) and 2.1 (range 1-8) in the low and intermediate tPSA group, respectively (P ¼ 0.56).
Overall only 210 (46.9%) patients were scored the same GS in the RRP specimen as in the Pbx (Table 2) . Statistically significant differences in the percentage of correctly assigned GS 6 were found in the two subgroups of different tPSA levels. Although in the tPSA group of 2-4 ng ml À1 54% (116) of patients had a postoperative GS 6 only 40.3% (94) in the 4-10 ng ml À1 tPSA group were scored correctly. In the low tPSA group, 32.6% (70) of GS 6 tumors were underscored and 43.8% (102) in the intermediate tPSA group, respectively. In both groups the majority of tumors upgraded were finally GS 7 (31.2% in the low and 37.3% in the intermediate tPSA group).
Statistically significant differences could be found in the number of positive cores obtained at biopsy between those patients who were correctly assigned and those who were upgraded later (1.84 vs 2.26, P ¼ 0.033). Table 3 lists the amount of possible over and under diagnosis. Over diagnosis was found in 68 patients, (Table 4) .
Discussion
Since the implementation of widespread tPSA-based PCa screening, more and more patients are being diagnosed with PCa at low stage and with favorable tumor grade (GS 6). These tumors are considered to have a low property to cause death and thus noninvasive treatment strategies are being offered to these individuals, whereas patients at higher risk are often confronted with more aggressive intervention. For example, biochemical recurrence is four times as high in patients with GS 7 compared with those with GS 6 after brachytherapy and therefore external beam radiation in addition to brachytherapy is recommended. 8, 9 Active surveillance is usually not offered to patients with higher grade, as the risk of progression is higher in these patients. Therefore, accurate grading is a crucial step in choosing the appropriate treatment regime.
However, several groups including ours showed that in up to 60% of cases initial Pbx mistakenly under grades tumors as GS 6. Pinthus et al. 4 have recently shown that 50% of all GS 6 tumors on Pbx were upgraded to GS 7.
In our series, 38.4% of all GS 6 biopsies were upgraded, 34.4% to GS 7. Differences in the number of under grading PCa at biopsy may be explained by the different biopsy techniques applied. It has been shown that the implementation of extended biopsies has led to a decrease in upgrading compared with sextant biopsy. 10 However, other studies have not shown that increasing the number of biopsy cores decreased the grading error rate. 11, 12 Differences in the number of upgrading were found in the tPSA groups of 2-3.9 and 4-10 ng ml À1 . Other groups could also show a relationship in the percentage of upgrading whereas others could not find any connection. 4, 13 Graif et al.
14 conducted a study 292 men with two or fewer positive GS 6 biopsy cores. Even in this kind of low volume disease upgrade to GS 7 was found in 78 patients (27%) and in 16% of patients other adverse pathological features as positive surgical margins occurred in the surgical specimens. In our study, tumors were more likely to be upgraded when the number of positive cores was higher. On the other hand, even in the upgrading group almost 42% of patients were diagnosed with PCa by only one positive core, indicating that a more aggressive tumor cannot be ruled out by a biopsy that results in a single positive GS 6 core.
Although there is evidence that biopsies often under grade tumors as GS 6, which are definitely GS 7 or higher, the implementation of widespread tPSA-based PCa screening with its detection of cancers at early stage has led to a considerable debate regarding potential over diagnosis. Opponents of screening suggest that some men are treated unnecessarily because they would not have been diagnosed with PCa without screening. [15] [16] [17] Therefore, active monitoring or watchful waiting is sometimes recommended rather than definitive therapy particularly for men who are diagnosed with low volume, low-grade disease and for whom immediate definitive therapy could potentially do more harm than good. 18 We investigated the amount of possible over and under diagnosis in men diagnosed GS 6 at biopsy. In both tPSA groups, a higher amount of under than of over diagnosis was found. Furthermore, under diagnosis occurred more often in patients wrongly under scored at biopsy. Even in the low tPSA group, in which cancers would not have been detected, if 4 ng ml À1 had been used as threshold for biopsy, there was considerable amount of under diagnosis, but fewer patients were upgraded to GS 7, where patients were significantly more often under diagnosed. Patients in the low tPSA level were furthermore younger at age (57.4 years vs 62.7 years). In addition to this point it is impossible to say with certainty in a young man if his tumor has been over diagnosed and radical treatment is unnecessary. Therefore, this study implicates that especially younger men with a life expectancy of more than 20 years profit from tPSA screening.
However, there are a few possible limitations of our study. First, the whole study population is screening population consisting of Caucasian European ancestry in Austria. Thus, results may not apply to other patient groups. A second possible limitation is that there were two biopsy techniques from 1996 to 2000 and 2000 to 2005. In our study of the influences of the different prostate biopsy techniques at our department there were no differences in the biological behavior of the PCa detected or of pathological stage. 6 Differences were noted in detection rates by core. Furthermore, we were not able to obtain data about how many biopsy cores were involved and how many percent of each core volume was affected, if PCa was diagnosed in this core. In addition, there are limitations concerning the estimation of under and over diagnosis, as they heavily depend on definitions used. Although the higher incidence of biochemical failure in margin positive cases may depend more on biological factors, not directly measurable, than on margin status, we included margin status in our definitions of over and under diagnosis. Even it is not possible to be certain whether a positive surgical margin occurred as a result of aggressive tumor biology and/or an error in surgical technique. 7 Despite the limitations, our study stresses out that the use of biopsy finding for clinical management needs 
